Background {#Sec1}
==========

Hepatocellular carcinoma (HCC) is the fifth most common tumor worldwide, and it is the second leading cause of cancer-related death in China \[[@CR1]\]. Liver resection is the mainstay curative treatment for early-stage HCC and selected intermediate-stage or advanced-stage HCC with preserved liver function \[[@CR2]\]. As the resection technique and perioperative management have improved, surgical morbidity and mortality following hepatectomy have substantially decreased \[[@CR3], [@CR4]\]. In particular, refined surgical manipulation involves reduced blood loss during liver resection; however, liver resection for HCC involves a high risk of bleeding due to underlying cirrhosis. The blood transfusion rate during liver resection has decreased from 66 to 22% in the past two decades \[[@CR5]\].

Blood transfusion is still a life-saving therapy when excessive intraoperative bleeding occurs, but it involves the risk of transfusion-related complications, such as transmission of hepatitis viruses, human immunodeficiency virus, and allergic reactions \[[@CR6]\]. Regarding oncologic outcomes, although many studies had been reported, the influence of perioperative blood transfusion (PBT) on postoperative survival outcomes is controversial \[[@CR7]--[@CR12]\]. Furthermore, the influence of PBT on different stage of resectable HCC has not been well investigated.

In this study, we focused on the impact of PBT on oncologic outcomes of patient with different stage of HCC after curative resection by using propensity score matching (PSM) analysis and Cox regression analysis.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

From January 2009 to November 2015, all consecutive patients with HCC undergoing curative liver resection (complete resection of gross tumors with a pathological tumor free margin) in the authors' department were evaluated for this study. Clinical data were entered prospectively in an HCC database and reviewed retrospectively. Patients with HCC with bile duct tumor thrombus or ruptured HCC treated with hepatectomy, those who died within 30 days postoperatively (surgical mortality) were excluded. This study was approved by the ethics committee of The First Affiliated Hospital of Sun Yat-sen University, and written informed consent was obtained from all patients.

Perioperative assessment {#Sec4}
------------------------

Preoperative evaluation of and resection criteria for HCC at our center were previously described \[[@CR13]\]. The treatment option was decided by the HCC multidisciplinary team. The Barcelona Clinic Liver Cancer (BCLC) staging system was used for HCC staging \[[@CR14]\]. Although we used the Child-Pugh score to evaluate liver function in clinical practice in this cohort of patients, we used albumin to bilirubin (ALBI) scores for data analysis because it was reported that they are more accurate and objective than conventional Child-Pugh scores \[[@CR15], [@CR16]\]. The neutrophil-to-lymphocyte ratio (NLR) was obtained by dividing the neutrophil count by the lymphocyte count. The platelet-to-lymphocyte ratio (PLR) referred to the platelet count subtracted from the lymphocyte count. The alanine transaminase (ALT)-to-platelet ratio index (APRI) was calculated as follows: \[ALT ÷ (upper limit of ALT × platelet count)\] × 100. These inflammatory parameters were transformed to binary variables in the Cox regression analysis by using their median values as the cutoff thresholds, respectively.

PBT referred to the transfusion of packed red blood cells (RBCs) during excessive intraoperative bleeding or postoperative bleeding complications. Transfusions of platelets, fresh-frozen plasma, and albumin were not included. The PBT criteria were preoperative anemia (hemoglobin ≤70 g/L) and excessive intraoperative or postoperative intra-abdominal bleeding with unstable hemodynamics or hemoglobin \< 70 g/L. Postoperative complications were graded by the Clavien-Dindo classification \[[@CR17]\].

Surgical procedures {#Sec5}
-------------------

Liver resection included anatomical resection (AR) and non-anatomical resection (NAR), which was introduced in our previous report \[[@CR13]\]. Briefly, AR was planned for central tumors, tumors with ipsilateral satellite nodules, or portal vein tumor thrombus (PVTT), and for patients with a sufficient liver remnant after AR. NAR was preferred for peripheral tumors and for patients with an insufficient liver remnant after AR was performed. The Pringle maneuver was applied if necessary. Major resection was defined as resection larger than three segments.

Propensity score matching analysis {#Sec6}
----------------------------------

To minimize the influence of patient selection bias and confounding variables between groups in this retrospective study, a PSM analysis was used \[[@CR18], [@CR19]\]. In this study, four levels of outcome-related variables, including patient and underlying liver disease-related \[age, sex, preoperative hemoglobin level, platelet count, positive HBsAg, cirrhosis, prothrombin time (PT), alanine transaminase (ALT) level, ALBI grade\], tumor-related \[tumor size, tumor number, tumor capsule, microvascular invasion (MVI), portal vein tumor thrombus (PVTT), hepatic vein tumor thrombus (HVTT), alpha fetoprotein (AFP) level, tumor differentiation\], systemic inflammation -- related (NLR, PLR, APRI), and procedure-related variables (extent of resection, resection type, resection margin, and Pringle maneuver), were included in the propensity score model to balance the baseline of groups as much as possible. PSM was performed using R software (R 2.15.3; <http://www.r-project.org>). A one-to-one nearest neighbor matching without replacement algorithm was applied. To obtain the best trade-off between homogeneity and retained sample size, caliper widths of 0.20, 0.10, 0.050, and 0.010 were tested in our cohort of patients. We found that a caliper width of 0.1 met the requirement.

Follow-up {#Sec7}
---------

The follow-up protocols for HCC and treatment of recurrent HCC at our center were described previously \[[@CR13]\]. The main outcomes of this study were disease free survival (DFS) and overall survival (OS). DFS was calculated from the date of tumor resection to the date of first tumor recurrence or the last follow-up visit. The OS was calculated from the date of tumor resection to the date of death or the date of the last follow-up visit. The endpoint follow-up was December 30, 2016. The median follow-up period was 51.0 months (range, 3--102 months). The treatments of recurrent HCC including radiofrequency ablation, re-hepatectomy, transarterial chemoembolization, or sorafenib alone or combined therapy based on the number, location of recurrent tumor and liver function reserve.

Statistical analysis {#Sec8}
--------------------

The clinical database was established using SPSS for Windows (version 22.0; IBM, Armonk, NY, USA). Continuous data are expressed as mean (standard deviation) or median (range). The independent *t* test or Mann-Whitney U test was used to compare continuous data between groups, and the χ^2^ test was used for discrete data. Cumulative DFS and OS rates were calculated using the Kaplan--Meier method and compared between groups using the log rank test. A Cox regression model involving univariable and multivariable analyses was used to identify risk factors associated with DFS and OS. All factors with statistical significance (*P* \< 0.05) in the univariable analysis were entered into the multivariable analysis (forward method) to yield independent risk factors. *P* \< 0.05 was considered statistically significant.

Results {#Sec9}
=======

A total of 1336 patients had surgery for HCC in this study period. Eighty-one patients were excluded from this study: 17 patients with bile duct tumor thrombus; 53 patients with rupture HCC; and 11 (0.9%, 11/1266) patients who died of postoperative liver failure. Finally, 1255 patients who underwent liver resection with curative intent were recruited in this study. Most patients (84.8%) had underlying HBV infection. 27.6% (347/1255) received PBT. The patients were classified into two subsets: the BCLC 0-A subset (*n* = 804, 64.1%) and the BCLC B-C subset (*n* = 451, 35.9%) according to tumor stage.

Patients' clinicopathologic features in the entire cohort {#Sec10}
---------------------------------------------------------

The baseline clinical data of patients with PBT and those without PBT (non-PBT) within the BCLC 0-A subset and the BCLC B-C subset were compared respectively and summarized in Table [1](#Tab1){ref-type="table"}. Numerous variables were significantly different between patients with PBT and those without PBT within each subset. 21.3% (171/804) of patients received PBT in the subset of BCLC 0-A, and 39.0% (176/451) in the BCLC B-C subset. Table 1Baseline characteristics of patients with PBT and those without PBT in different HCC stage subset in the entire cohort (*n* = 1255)*Variable*BCLC 0-A (*n* = 804)BCLC B-C (*n* = 451)PBT\
*n* = 171)Non-PBT\
(*n* = 633)*P*-valuePBT\
(*n* = 176)Non-PBT\
(*n* = 275)*P*-value*Demographic factors* Age, yr52.9 ± 12.550.9 ± 12.10.06249.9 ± 12.249.1 ± 12.50.544Sex, n (%) Male139 (81.3)557 (88.0)0.220157 (89.2)249 (90.5)0.644 Female32 (18.7)76 (12.0)19 (10.8)26 (9.5)HBsAg, n (%) Positive143 (83.6)545 (86.1)0.415148 (84.1)228 (82.9)0.743 Negative28 (16.4)88 (13.9)28 (15.9)47 (17.1)Cirrhosis, n (%) Yes123 (71.9)427 (67.5)0.265133 (75.6)198 (72)0.404 No48 (28.1)206 (32.5)43 (24.4)77 (28)Hemoglobin, g/L129.7 ± 22.8141.6 ± 17.5\< 0.001131.2 ± 23.1140.3 ± 19.90.000Platelet count, × 10^9^ /L185.0 ± 64.5201.3 ± 92.90.008215.4 ± 113.3207.1 ± 71.30.338Prothrombin time, s13.0 ± 1.612.7 ± 0.90.00113.1 ± 1.112.7 ± 1.30.001ALT, U/L, median (range)39 (6565)33 (71428)0.02442.5(8237)38.0(6522)0.189ALBI grade, n (%) Grade 184 (49.1)399 (63.0)\< 0.00176 (43.2)160 (58.2)0.001 Grade 284 (49.1)232 (36.7)99 (56.3)115 (41.8) Grade 33 (1.8)2 (0.3)1 (0.5)0*Inflammatory factors* NLR, median (range)2.4 (0.5,13.0)1.9 (0.3,24.9)\< 0.0012.5 (0.9,24.4)2.3 (0.6,18.3)0.013 PLR, median (range)121.1 (21.61432.1)96.9 (19.4414.0)\< 0.001133.9 (19.8751.0)119.6 (20.6314.6)\< 0.001 APRI, median (range)0.6 (0.1,12.2)0.5 (0.1,21.1)0.0380.6 (0.1,3.8)0.5 (0.1,5.7)0.079*Tumor characteristics* AFP, ug/L   ≥ 40099 (42.1)214 (33.8)0.04488 (50)149 (54.2)0.387   \< 40072 (57.9)419 (66.2)88 (50)126 (45.8)  Tumor size, cm9.2 ± 6.16.2 ± 3.1\< 0.00110.7 ± 3.928.9 ± 3.5\< 0.001Tumor number, n (%) Solitary167 (97.7)596 (94.2)0.04959 (33.5)87 (31.6)0.975 24 (2.3)29 (4.6)59 (33.5)102 (37.1) 30 (0)8 (1.2)18 (10.2)25 (9.1) 40 (0)0 (0)40 (22.8)61 (22.2)Tumor capsule, n (%) Complete137 (80.1)574 (90.7)\< 0.001107 (60.8)187 (68)0.118 Incomplete34 (19.9)59 (9.3)69 (39.2)88 (32)Differentiation, n (%) I+ II115 (67.3)465 (73.5)0.108119 (67.6)193 (70.2)0.566 III, IV56 (32.7)168 (26.5)57 (32.4)82 (29.8)MVI, n (%) Yes50 (29.2)123 (19.4)0.00679 (44.9)105 (38.2)0.158 No121 (70.8)510 (80.6)97 (55.1)170 (61.8)PVTT, n (%) Yes00100 (56.8)116 (42.2)0.002 No171 (100)633 (100)76 (43.2)159 (57.8)HVTT, n (%)0.000 Yes0021 (11.9)7 (2.5) No171 (100)633 (100)155 (88.1)268 (97.5)*Surgical factors* Extent of resection, n (%)  Major64 (37.4)194 (30.6)0.092126 (71.6)180 (65.5)0.174  Minor107 (62.6)439 (69.4)50 (28.4)95 (34.5)Type of resection, n (%) Anatomical62 (36.3)203 (32.1)0.30297 (55.1)150 (54.5)0.906  Nonanatomical109 (63.7)430 (67.9)79 (44.9)125 (45.5)Resection margin  ≤ 1 cm32 (18.7)58 (9.2)\< 0.00156 (31.8)122 (44.4)0.008  \> 1 cm139 (81.3)575 (90.8)120 (68.2)153 (55.6)Pringle maneuver, n (%) Yes111 (64.9)380 (60.0)0.245114 (64.8)169 (61.4)0.477 No60 (35.1)253 (40.0)62 (35.2)106 (38.6) Blood loss, ml, median (range)1484.7 (200,12,000)200 (50,3000)\< 0.0011000 (200,10,500)300 (30,2500)\< 0.001Clavien-Dindo grade I4 (2.3)9 (1.4)0.0453 (1.7)8 (2.9)0.950 II1 (0.6)9 (1.4)2 (1.1)4 (1.5) III15 (8.8)31 (4.9)10 (5.7)18 (6.5) IV2 (1.2)3 (0.5)3 (1.7)2 (0.7)Abbreviation: *HBsAg* Hepatitis B surface antigen, *ABLI grade* albumin to bilirubin grade, *ALT* anlanine transaminase, *NLR* neutrophil to lymphocyte ratio, *PLR* platelet to lymphocyte ratio, *APRI* alanine transaminase to platelet ratio index, *PVTT* portal vein tumor thrombus, *HVTT* hepatic vein tumor thrombus, *MVI* microscopic vascular invasion, *AFP* alpha fetoprotein

Survival impact of PBT on different stages of HCC in the entire cohort {#Sec11}
----------------------------------------------------------------------

In the subset of BCLC 0-A, the median DFS was 12.0 months (95% confidence interval \[CI\]: 7.9--16.1) for PBT group and 43.1 months (95% CI: 28.5--57.8) for the non-PBT group (*P* \< 0.001) (Fig. [1](#Fig1){ref-type="fig"}a). The median OS was 36.0 months (95%CI: 25.0--47.0) for the PBT group and 96.0 months for the non-PBT group (*P* \< 0.001) (Fig. [1](#Fig1){ref-type="fig"}b). In the subset of BCLC B-C, the median DFS was 5.0 months (95% CI: 3.8--6.2) for PBT group and 7.0 months (95% CI: 4.6--9.4) for the non-PBT group (*P* = 0.006) (Fig. [1](#Fig1){ref-type="fig"}c). The median OS was 20.0 months (95%CI: 14.5--25.5) for the PBT group and 44.0 months for the non-PBT group (*P* = 0.004) (Fig. [1](#Fig1){ref-type="fig"}d). Fig. 1Survival curves of patients with PBT and without PBT in the BCLC 0-A subset and the BCLC B-C subset in the entire cohort. **a** DFS in the BCLC 0-A subset. **b** OS in the BCLC 0-A subset. **c** DFS in the BCLC B-C subset. **d** OS in the BCLC B-C subset (Log rank test)

Propensity score matching analysis {#Sec12}
----------------------------------

Because numerous variables were different between the PBT group and the non-PBT group in each subset of patients, a large patient selection bias existed for the entire cohort. To overcome this selection bias, PSM was used. Twenty-four variables, including patient and underlying liver disease-related, tumor-related, systemic inflammation-related, and procedure-related factors were selected as the matched factors and entered in the PSM model. After matching, 288 pairs of patients were generated from those with PBT and without PBT. In the matched cohort, apart from blood loss, the confounding variables of the matched groups in each subset were similar (Table [2](#Tab2){ref-type="table"}). The postsurgical complication rates were comparable between patients with PBT and those without PBT within the BCLC 0-A subset and the BCLC B-C subset, respectively. Table 2Baseline characteristics of patients with PBT and those without PBT in different HCC stage subset in the matched cohort (*n* = 576)*Variable*BCLC 0-A (*n* = 317)BCLC B-C (*n* = 259)PBT\
*n* = 156)Non-PBT\
(*n* = 161)*P*-valuePBT\
(*n* = 132)Non-PBT\
(*n* = 127)*P*-value*Demographic factors* Age, yr52.7 ± 12.353.1 ± 12.40.78749.2 ± 12.651.4 ± 13.10.182Sex, n (%) Male127 (81.4)126 (78.3)0.487118 (89.4)115 (90.6)0.758 Female29 (18.6)35 (21.7)14 (10.6)12 (9.4)HBsAg, n (%) Positive132 (84.6)138 (85.7)0.784112 (84.8)103 (81.1)0.424 Negative24 (15.4)23 (14.3)20 (15.2)24 (18.9)Cirrhosis, n (%) Yes144 (73.1)121 (75.2)0.674101 (76.5)93 (73.2)0.544 No42 (26.9)40 (24.8)31 (23.5)34 (26.8) Hemoglobin, g/L132.0 ± 21.5133.4 ± 19.80.548136.3 ± 21.1133.4 ± 19.40.245 Platelet count, ×10^9^ /L201.8 ± 93.3180.6 ± 71.30.023197.8 ± 85.0207.9 ± 73.40.307 Prothrombin time, s12.9 ± 1.612.9 ± 0.10.70513.0 ± 1.113.0 ± 1.10.894 ALT, U/L, median (range)38 (6293)34 (71428)0.93144 (8, 237)38 (12,522)0.541ALBI grade, n (%) Grade 182 (52.5)77 (47.8)0.48664 (48.4)53 (41.7)0.341 Grade 272 (46.2)83 (51.6)67 (50.8)74 (58.3) Grade 32 (1.3)1 (0.6)1 (0.8)0*Inflammatory factors* NLR, median (range)2.2 (0.52,13.03)2.1 (0.3, 24.9)0.9042.3 (0.9, 24.4)2.5 (1.1, 15.8)0.901 PLR, median (range)117.8 (21.4, 405.4)107.8 (19.4, 414.0)0.379118.4 (19.8, 460.3)131.1 (20.6, 314.6)0.440 APRI, median (range)0.5 (0.1, 5.3)0.5 (0.1, 21.1)0.6210.6 (0.1, 3.8)0.5 (0.1, 5.7)0.269*Tumor characteristics* AFP, ug/L   ≥ 40064 (41.0)60 (37.3)0.49361 (46.2)70 (55.1)0.153   \< 40092 (59.0)101 (68.9)71 (53.8)57 (44.9)  Tumor size, cm8.4 ± 4.47.69 ± 3.860.1109.8 ± 3.510.1 ± 3.50.441Tumor number, n (%) Solitary153 (98.1)156 (96.7)0.50238 (28.8)45 (35.4)0.524 23 (1.9)5 (3.1)48 (36.4)45 (35.4) 30016 (12.1)4 (3.2) 40030 (22.7)33 (26.0)Tumor capsule, n (%) Complete127 (81.4)135 (83.9)0.56886 (65.2)81 (63.8)0.818 Incomplete29 (18.6)26 (16.1)46 (34.8)46 (36.2)Differentiation, n (%) I+ II108 (69.2)111 (68.9)0.95688 (66.7)85 (66.9)0.964 III, IV48 (30.8)50 (16.1)44 (33.3)42 (33.1)MVI, n (%) Yes35 (22.4)33 (20.5)0.67462 (47.0)66 (52.0)0.196 No121 (77.6)128 (79.5)70 (53.0)61 (48.0)PVTT, n (%) Yes0068 (51.5)72 (56.7)0.405 No156 (100)161 (100)64 (48.5)55 (43.3)HVTT Yes009 (6.8)5 (3.9)0.307 No156 (100)161 (100)123 (93.2)122 (96.1)*Surgical factors* Extent of resection, n (%)  Major59 (37.8)58 (36.0)0.74191 (68.9)83 (65.4)0.541  Minor97 (62.2)103 (64.0)41 (31.1)44 (34.6)Type of resection, n (%) Anatomical55 (35.3)53 (32.9)0.66268 (51.5)69 (54.3)0.651 nonanatomical101 (64.7)108 (67.1)64 (48.5)58 (45.7)Resection margin, cm  ≤ 151 (32.7)45 (28.0)0.35899 (75.0)100 (78.7)0.476  \> 1105 (67.3)116 (72.0)33 (25.0)27 (21.3)Pringle maneuver, n (%) Yes56 (35.9)46 (28.6)0.163100 (75.7)98 (77.2)0.790 No100 (64.1)115 (71.4)32 (24.3)29 (22.7)Blood loss, ml, median (range)^a^1000 (50, 12,000)200 (50,3000)\< 0.0011000 (15,7000)300 (50,2500)\< 0.001Clavien-Dindo grade^a^ I3 (1.9)3 (1.9)0.9231 (0.8)4 (3.1)0.689 II1 (0.6)3 (1.9)1 (0.8)2 (1.6) III12 (7.7)12 (7.5)6 (4.5)7 (5.5) IV2 (1.3)1 (0.6)2 (1.5)1 (0.8)^a^Variables are not included in the matching modelAbbreviation: *ABLI grade* albumin to bilirubin grade, *ALT* anlanine transaminase, *NLR* neutrophil to lymphocyte ratio, *PLR* platelet to lymphocyte ratio, *APRI* alanine transaminase to platelet ratio index, *PVTT* portal vein tumor thrombus, *HVTT* hepatic vein tumor thrombus, *MVI* microscopic vascular invasion, *AFP* alpha fetoprotein, *PLR* platelet to lymphocyte ratio

Survival impact of PBT on different stage of HCC in the matched cohort {#Sec13}
----------------------------------------------------------------------

There were 317 (55.0%) patients with BCLC stage 0-A, and 259 (45.0%) BCLC stage B-C in the matched cohort (Table [2](#Tab2){ref-type="table"}). The median DFS of patients with PBT was significantly shorter than that without PBT in the BCLC stage 0-A subset (12.0 months \[95%CI, 7.4--16.6\] vs. 36.0 months \[95% CI: 10.6--61.4\], *P* = 0.001, Fig. [2](#Fig2){ref-type="fig"}a). Similar result was observed for OS (36.0 months \[95% CI, 23.9--48.0\] vs. 96.0 months \[95% CI: 14.6--177.4\], *P* = 0.001, Fig. [2](#Fig2){ref-type="fig"}b). However, the median DFS and median OS were comparable between patients with PBT and those without PBT in the subset of BCLC stage B-C HCC (both *P* \> 0.05, Fig. [2](#Fig2){ref-type="fig"}c, d). Fig. 2Survival curves of patients with PBT and without PBT in the BCLC 0-A subset and the BCLC B-C subset in the matched cohort. **a** DFS in the BCLC 0-A subset. **b** OS in the BCLC 0-A subset. **c** DFS in the BCLC B-C subset. **d** OS in the BCLC B-C subset (Log rank test)

Risk factors affecting DFS and OS {#Sec14}
---------------------------------

To further investigate the role of PBT in survival outcomes of HCC, the Cox regression model was used to identify the risk factors associated with DFS and OS of the entire cohort. Twenty-three clinicopathologic variables were included in the univariable analysis (Table [3](#Tab3){ref-type="table"}). The variables with statistical significance (*P* \< 0.05) were selected and entered the multivariable analysis (Table [4](#Tab4){ref-type="table"}). The results revealed that PBT had an increased risk of DFS (hazard ratio \[HR\], 1.607; 95% CI,1.272--2.031; *P* \< 0.001) and OS (HR, 1.756, 95% CI,1.302--2.368; *P* \< 0.001) for patients with stage 0-A HCC after curative resection. However, PBT was not a risk factor of DFS or OS for patients with stage B-C HCC (both *P* \> 0.05). Table 3Risk factors associated with postoperative disease free survival and overall survival identified by univariate Cox regression analysis in the entire cohortVariablesUnivariate AnalysisOverall survivalDisease-free survivalHazard ratio***p-valule***Hazard ratio***p-value*Age, year**  ≤ 50 vs \> 500.991 (0.983--0.999)0.0250.715(0.617--0.829)\< 0.001**Sex** Male vs female0.953 (0.710--1.278)0.7460.789(0.622--0.999)0.049**HbsAg** Positive vs negative1.013 (0.777--1.320)0.9241.049(0.855--1.288)0.646**Cirrhosis** Yes vs no1.230 (0.990--1.529)0.0621.325(1.119--1.568)0.001**ALBI grade** 2 + 3 vs 11.561 (1.291--1.886)\< 0.00011.218(1.052--1.409)0.008**ALT, U/L**  \> 40 vs ≤ 401.199 (0.987--1.457)0.0681.254(1.082--1.455)0.003**Platelet. ×10**^**9**^**/L**  ≤ 100 vs \> 1001.007 (0.690--1.469)0.9721.083**(**0.810--1.448**)**0.590**NLR**  \> 2.3 vs ≤ 2.31.102 (1.070--1.134)\< 0.0011.058**(**1.030--1.087**)**\< 0.001**PLR**  \> 118.9 vs ≤ 118.91.002 (1.000--1.003)\< 0.0011.002(1.001--1.002)\< 0.001**APRI**  \> 0.55 vs ≤ 0.550.934 (0.724--1.206)0.6011.001(0.847--1.184)0.988**Tumor size, cm**  \> 5.0 vs ≤ 5.02.353 (1.792--3.090)\< 0.0011.832**(**1.523--2.204**)**\< 0.001**Tumor number** Multiple vs solitary1.906 (1.554--2.336)\< 0.0011.768(1.432--2.183)\< 0.001**Tumor capsule** Incomplete vs complete0.474 (0.382--0.588)\< 0.0010.587(0.494--0.698)\< 0.001**Differentiation** 3 + 4 vs 1 + 21.170 (0.948--1.443)0.1451.183(1.007--1.389)0.041**Macro-VTT** Yes vs no3.295 (2.660--4.083)\< 0.0012.411(2.026--2.869)\< 0.001**MVI** Yes vs no2.347 (1.925--2.860)\< 0.0011.944(1.664--2.270)\< 0.001**AFP, μg/L**  \> 400 vs ≤ 4001.841(1.516--2.236)\< 0.0011.608(1.386--1.864)\< 0.001R**esection margin, cm**  ≤ 1.0 vs \> 1.01.050 (0.998--1.521)0.3540.865 (0.775--1.211)0.746**Pringle maneuver** Yes vs no0.886 (0.815--0.956)0.2340.786 (0.705--0.898)0.846**Resection type** Anatomic vs nonanatomic1.366 (1.125--1.660)0.021.375 (1.185--1.595)\< 0.001**Resection extent** Major vs minor1.728 (1.422--2.099)\< 0.0011.702 (1.468--1.974)\< 0.001**Blood loss, ml**  \> 800 **vs** ≤ 8002.217(1.807--2.720)\< 0.0011.761(1.494--2.075)\< 0.001**Blood transfusion** Yes vs no2.107 (1.726--2.571)\< 0.0011.759 (1.503--2.058)\< 0.001Abbreviation: *HBsAg* hepatitis B virus surface antigen, *ALT* anlanine transaminase, *NLR* indicates neutrophil to lymphocyte ratio, *PLR* platelet to lymphocyte ratio, *APRI* alanine transaminase to platelet ratio index, *AFP* alpha fetoprotein, *MVI* microscopic vascular invasion, *Macro-VTT* macroscopic venous tumor thrombus, including portal vein tumor thrombus and hepatic vein tumor thrombusTable 4Risk factors associated with postoperative disease free survival and overall survival identified by multivariate Cox regression analysisVariablesOSDFSHR (95% CI)*p*-valueHR (95% CI)*p*-value*The entire cohort (n = 1255)* Age, yr, ≤50 vs \> 500.800 (0.688--0.931)0.004 Cirrhosis, yes vs no1.328 (1.117--1.578)0.001 ALBI grade, 2 + 3 vs 11.225 (1.005--1.494)0.044 NLR, \> 2.3 vs ≤ 2.31.080 (1.041--1.121)\< 0.0011.034 (1.002--1.068)0.040 Tumor size, cm, \> 5 vs ≤ 51.437 (1.077--1.916)0.0141.311 (1.073--1.602)0.008 Tumor no., multiple vs solitary1.489 (1.206--1.838)\< 0.0011.583 (1.343--1.866)\< 0.001 Macro-VTT, yes vs no1.662 (1.288--2.143)\< 0.0011.377 (1.126--1.685)0.002 MVI, yes vs no1.581 (1.262--1.980)\< 0.0011.541 (1.298--1.829)\< 0.001 AFP, μg/L, \> 400 vs ≤ 4001.412 (1.154--1.726)0.0011.267 (1.086--1.477)0.003 PBT, yes vs no1.623 (1.312--2.008)\< 0.0011.365 (1.158--1.608)\< 0.001*BCLC 0-A subgroup (n = 804)* Age, yr, ≤50 vs \> 500.986 (0.977--0.994)0.001 Cirrhosis, yes vs no1.325 (1.053--1.668)0.016 ALBI grade, 2 + 3 vs 11.434 (1.094--1.879)0.009 NLR, \> 2.3 vs ≤ 2.31.105 (1.056--1.157)\< 0.0011.054 (1.010--1.099)0.016 MVI, yes vs no1.643 (1.217--2.220)0.0011.578 (1.252--1.988)\< 0.001 AFP, μg/L, \> 400 vs ≤ 4001.832 (1.390--2.413)\< 0.0011.445 (1.167--1.789)0.001 PBT, yes vs no1.756 (1.302--2.368)\< 0.0011.607 (1.272--2.031)\< 0.001*BCLC B-C subgroup (n = 451)* Age, yr, ≤50 vs \> 500.989 (0.980--0.999)0.025 Tumor size, cm, \> 5 vs ≤ 51.826 (1.151--2.897)0.011 Tumor no., multiple vs solitary1.546 (1.129--2.116)0.007 PLR, \> 118.9 vs ≤ 118.91.002 (1.000--1.003)0.013 MVI, yes vs no1.492 (1.059--2.102)0.0221.568 (1.253--1.961)\< 0.001 Macro-VTT, yes vs no2.033 (1.411--2.929)\< 0.0011.367 (1.067--1.752)0.011 Cirrhosis, yes vs no1.408 (1.083--1.830)0.014 PBT, yes vs no1.257 (0.929--1.700)0.1391.203 (0.950--1.525)0.126Abbreviation: *OS* overall survival, *DFS* disease free survival, *HR* hazard ratio, *95% CI* 95% confident interval, *ABLI grade* albumin to bilirubin grade, *NLR* neutrophil to lymphocyte ratio, *Macro-VTT* macroscopic venous tumor thrombus, *MVI* microscopic vascular invasion, *AFP* alpha fetoprotein, *PBT* perioperative blood transfusion, *PLR* platelet to lymphocyte ratio

Discussion {#Sec15}
==========

The impact of PBT on survival outcomes for HCC has been debated for more than two decades \[[@CR7]--[@CR12], [@CR20]--[@CR24]\]. Because an RCT is impossible on the issue of blood transfusions in clinical practice, all evidences available were based on retrospective study. In 2013, one meta-analysis involved 22 retrospective studies with 5635 patients concluded that PBT had a negative effect on oncologic outcomes for HCC after resection \[[@CR12]\]. However, five studies published recently still yielded controversial conclusions, although they all deliberately used a PSM analysis to adjust patient selection bias \[[@CR7]--[@CR11]\].

Resectable HCC comprised of different stage of disease, from BCLC stage 0 to C, which had large heterogeneity among patients and tumors. The prominent independent risk factors associated with recurrence or OS should be various for different stage of tumor. In the present study, we focused on the impact of PBT on HCC patient with different tumor stage and demonstrated that both DFS and OS for patients with PBT were significantly worse than those without PBT either within the BCLC 0-A subset (Fig. [1](#Fig1){ref-type="fig"}a, b) or the BCLC B-C subset (Fig. [1](#Fig1){ref-type="fig"}c, d) in the entire cohort.

Because the baseline variables of the PBT and non-PBT group within the BCLC 0-A subset or the BCLC B-C subset were diverse, patient selection bias largely existed. The patients with PBT had larger tumor burden (i.e., large tumors, multiple tumors, incomplete tumor capsules, PVTT, MVI, high levels of AFP) and higher level of inflammatory indexes (NLR, PLR and APRI) compared with those with non-PBT (Table [1](#Tab1){ref-type="table"}). These are all well-known risk factors associated with tumor recurrence and reduced survival \[[@CR25]--[@CR31]\], as partially confirmed by the present Cox regression analysis (Table [4](#Tab4){ref-type="table"}). This probably explains why the outcomes were worse for the patients with PBT than for those without PBT in the entire cohort.

Therefore, to overcome patient selection bias, PSM that could mimic an RCT study \[[@CR32]\] was used. Considering that HCC recurrence is induced cooperatively by tumor-related, underlying liver disease-related, systemic inflammation-related, and procedure-related factors, the matched variables in the PSM model should comprehensively include these four outcome-related aspects to reduce selection bias as much as possible. Inclusion of more outcome-related variables in PSM would potentially reduce selection bias \[[@CR33], [@CR34]\]. Notably, there were 24 variables that fully covered the four aspects of risk factors described in our PSM model. The comprehensive inclusion of matched variables would maximally reduce patient selection bias in our study.

Cirrhosis, tumor size, macroscopic venous tumor thrombus and intraopeative blood loss were reported to be the risk factors associated with PBT \[[@CR9], [@CR11]\]. Excessive blood loss is the most important cause of PBT. PBT or blood loss, which one is the prominent factor affecting oncologic outcome is clinically hard to define, although a previous study showed that blood loss predicted recurrence and poor OS \[[@CR35]\]. In the present study, Cox univariable analysis showed that both blood loss and PBT were significant risk factors of DFS and OS (Table [3](#Tab3){ref-type="table"}). However, it was PBT rather than blood loss affecting both DFS and OS in multivariable analysis (Table [4](#Tab4){ref-type="table"}). Therefore, we believed although blood loss was not adjusted as a selected factor for propensity matching, it would not potentially affect the survival results derived from the matched cohort.

After propensity matching, the baselines of patients with PBT and those without PBT were comparable (Table [2](#Tab2){ref-type="table"}) within the BCLC 0-A subset or the BCLC B-C subset. The survival results showed that PBT significantly reduced postoperative DFS and OS of HCC patients with BCLC stage 0-A (Fig. [2](#Fig2){ref-type="fig"}a, b), but it no longer influence the postsurgical survival outcomes of those with BCLC stage B-C (Fig. [2](#Fig2){ref-type="fig"}c, d). These were consistent with an early study reported by Ashara et al. in 1999, but our study had superiority in patient number and statistical power. In that study, only 175 patients were included and PSM was not applied to control patient bias \[[@CR36]\].

27.6% patients required blood transfusion in the entire cohort, but they all achieved curative resection (complete resection of gross tumors with a pathological tumor free margin). Therefore, the volume of intraoperative blood loss does not correlate with the curativity of resection for HCC. To further evaluate the impact of PBT on survival outcomes of HCC, Cox univariable and multivariable regression analyses were performed in the matched cohort. The results showed that PBT, but not blood loss was associated with a reduced DFS and OS (Table [4](#Tab4){ref-type="table"}). PBT was significantly associated with increased risks of poor DFS and OS for the subset of patients with BCLC stage 0-A HCC. However, in the BCLC B-C subset, PBT was not a risk factor affecting DFS and OS. Tumor-related factors (multiple tumor, size, venous tumor thrombus, MVI) are the major risk factors associated with tumor recurrence and OS. In the subset with early tumor, patients with PBT had a shorter DFS or OS may partially result from transfusion-related immunomodulation (TRIM) \[[@CR37]\]. Residual leukocyte or apoptotic cells in the stored RBCs may stimulate TGFβ and TNFα production, which in turn suppresses NK cells and activate Treg cells. Furthermore, microparticles derived from RBCs may contribute to neutrophil priming and activation and promotion of inflammation. These collectively caused immunosuppression \[[@CR38]\], thereby promoting tumor recurrence.

This study had several limitations. First, it was a retrospective cohort study, not an RCT trial. However, the large sample size and the combination of PSM (full inclusion of variables and appropriate calipers) and Cox regression analyses strengthened the statistical data, thereby yielding reliable results. Second, it was a single-center study, and most patients had hepatitis B virus-related HCC. External validation by other independent cohorts with different HCC etiologies is needed.

Conclusions {#Sec16}
===========

The present study demonstrated that PBT would significantly reduce DFS and OS of patients with BCLC stage 0-A HCC, but not those of patients with BCLC stage B-C HCC after curative liver resection. Deliberate preoperative planning and refined intraoperative manipulation are required to minimize blood loss and transfusion, thereby improving outcomes of HCC.
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